Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâ€™s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patientâ€™s own red blood cells. The Companyâ€™s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patientâ€™s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/02/26	0.2255 $	-63.03%	179,960,386
11/02/26	0.6100 $	+15.60%	841,538,273
10/02/26	0.5277 $	+305.92%	1,593,495,428
09/02/26	0.1300 $	-6.54%	38,110,029
06/02/26	0.1391 $	-4.79%	4,948,591

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.2255USD

Average target price

-USD

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 05:00:00 13/02/2026 HKT			5-day change	1st Jan Change
0.2255 ^USD	-63.03%		+54.35%	-93.27%

02-03	Quince Therapeutics, Inc. Announces Resignation of Board of Directors Members, Effective January 30, 2026	CI
01-30	Quince Therapeutics, Inc. Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia	CI

Capitalization	12.56M 10.58M 9.66M 9.22M 17.12M 1.14B 17.7M 112M 44.61M 548M 47.09M 46.12M 1.91B	P/E ratio 2025 *	-0.2x	P/E ratio 2026 *	-0.27x
Enterprise value	12.56M 10.58M 9.66M 9.22M 17.12M 1.14B 17.7M 112M 44.61M 548M 47.09M 46.12M 1.91B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	86.48%	Yield 2025 *	-	Yield 2026 *	-

02-03	Quince Therapeutics, Inc. Announces Resignation of Board of Directors Members, Effective January 30, 2026	CI
01-30	Quince Therapeutics, Inc. Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia	CI
01-30	Quince Therapeutics Halts Development of Neurological Drug Candidate; Shares Plunge	MT
12-15	Quince marks final patient visit in NEAT phase 3 study	RE
12-15	Quince Therapeutics, Inc. Announces Last Patient Last Visit in Phase 3 Neat Clinical Trial in Patients with Ataxia-Telangiectasia	CI
11-13	Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Quince Therapeutics, Inc. Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia	CI
10/10/25	Quince Therapeutics, Inc. Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia At 54Th Child Neurology Society Annual Meeting	CI
03/10/25	Quince Therapeutics, Inc. - Analyst/Investor Day
26/09/25	Quince Therapeutics, Inc. Announces the Publication of an Advanced Population Pharmacokinetic (PK) Modeling Study of Pediatric Patients with Ataxia-Telangiectasia and Healthy Adults Treated with Its Phase 3 Lead Asset, eDSP	CI
24/09/25	Quince Therapeutics, Inc. - Special Call
12/08/25	Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/08/25	Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP	CI

24/03/25	Oppenheimer Initiates Quince Therapeutics at Outperform	MT
09/03/22	HC Wainwright Adjusts Cortexyme's Price Target to $15 From $30, Reiterates Buy Rating	MT
28/01/22	Canaccord Genuity Downgrades Cortexyme to Hold From Buy	MT
27/01/22	JMP Securities Downgrades Cortexyme to Market Perform From Market Outperform	MT
11/11/21	Citigroup Adjusts Cortexyme's Price Target to $2 From $5, Maintains Sell Rating	MT

Quince Therapeutics, Inc. Stock

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Valuation: Quince Therapeutics, Inc.

Chart: Quince Therapeutics, Inc.

Latest news: Quince Therapeutics, Inc.

Last Transcript: Quince Therapeutics, Inc.

Analysts' recommendations: Quince Therapeutics, Inc.

Press Releases: Quince Therapeutics, Inc.

News in other languages: Quince Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Quince Therapeutics, Inc.

ETFs: Quince Therapeutics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-12	Micro-Caps Under $1: TOON, PRSO, RENX, QNCX, KIDZ Building Momentum	AQ
02-10	Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives	BU
01-30	Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia	BU
01-29	Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting	BU
01-22	Quince Therapeutics : Statement of Changes in Beneficial Ownership (Form 4)	PU

1 day	-63.03%
1 week	+54.35%
Current month	+32.65%
1 month	-92.36%
3 months	-86.81%
6 months	-87.68%
Current year	-93.27%

1 week	0.13	0.98
1 month	0.13	3.72
Current year	0.13	3.72
1 year	0.13	4.55
3 years	0.13	4.55
5 years	0.13	121.98
10 years	0.13	121.98

Manager	Title	Age	Since
Dirk Thye CEO	Chief Executive Officer	56	19/05/2022
Charles Ryan PSD	President	61	01/09/2023
Brendan Hannah DFI	Director of Finance/CFO	41	16/03/2023

Director	Title	Age	Since
David Lamond CHM	Chairman	51	01/02/2022
Christopher Senner BRD	Director/Board Member	58	01/03/2019
Dirk Thye BRD	Director/Board Member	56	19/05/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
QUINCE THERAPEUTICS, INC.	-63.03%	+54.35%	-83.89%	-75.75%	12.56M
LONZA GROUP AG	-1.74%	-3.90%	-16.81%	-8.35%	45.48B
BEONE MEDICINES AG	-1.38%	-0.17%	+55.13%	+41.70%	38.33B
CELLTRION, INC.	-0.42%	+9.66%	+38.80%	+60.37%	36.26B
IQVIA HOLDINGS INC.	-4.70%	-6.69%	-14.64%	-24.23%	28.64B
REVOLUTION MEDICINES, INC.	-0.67%	+1.23%	+131.74%	+295.97%	18.82B
IONIS PHARMACEUTICALS, INC.	-3.05%	-2.04%	+165.18%	+109.69%	13.25B
ASCENDIS PHARMA A/S	-1.53%	+0.33%	+72.90%	+91.40%	13.39B
EUROFINS SCIENTIFIC SE	-1.05%	-6.49%	+26.82%	-5.13%	13.41B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+8.61%	+15.76%	+29,391.87%	+3,835.45%	14.35B
Average	-6.90%	+6.08%	+2,976.71%	+432.11%	22.19B
Weighted average by Cap.	-1.11%	+0.31%	+1,938.05%	+297.07%

	2025 *	2026 *
Net sales	-	-
Net income	-55.33M -46.63M -42.55M -40.62M -75.43M -5.01B -78M -494M -197M -2.41B -208M -203M -8.43B	-33.33M -28.09M -25.64M -24.47M -45.44M -3.02B -46.99M -298M -118M -1.45B -125M -122M -5.08B
Net Debt	-	-